Published in TB and Outbreaks Week, June 15th, 2004
Severe CAP is defined as pneumonia contracted outside of a hospital setting that requires the patient's admission to an intensive-care unit. Tifacogin, developed by Chiron, is a recombinant form of tissue factor pathway inhibitor, or TFPI, a naturally occurring protein in the body.
"The mortality rate associated with severe CAP has remained constant for the past 50 years in spite of significant advances in antibiotic therapy. We believe that tifacogin has the potential to impact this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week